Sign in
CompletedNo phase

China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese Population

Key facts

Who runs it
Edwards Lifesciences
Where
China4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
58 people enrolled
Started
23 May 2018
Ended
19 Jun 2024
Type of study
Interventional
Treatments tested
  • SAPIEN 3 THV with the Commander delivery system
Record updated
10 September 2025

Who can take part

Age
60 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (10)Hide the full registry criteria

Who can take part

  • Subjects who are considered to be operable and high risk for surgical valve replacement: STS Score ≥ 8 and ≤ 15 or Logistic EuroSCORE ≥ 15 and ≤ 40. If STS score is below 8 and Logistic EuroSCORE is below 15, patients should have other clinical or anatomical risk factors that would be considered high risk for surgery and documented by the heart team
  • Severe symptomatic aortic stenosis requiring aortic valve replacement characterized by one or more of the following within 60 days prior to the index procedure: AVA < 0.8 cm2, Indexed AVA <0.5 cm2/m2, mean gradient > 40mmHg, or peak aortic jet velocity > 4.0m/sec
  • NYHA Functional Class II or greater
  • The study patient or the study patient's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the EC of the respective clinical site
  • The study patient agrees to comply with all required postprocedure follow-up visits

Who cannot take part

  • Evidence of an acute myocardial infarction ≤ 1 month (30 days) before the intended treatment
  • Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation >3+)
  • Aortic valve is bicuspid and the patient is less than 60 years old, or the aortic valve is bicuspid with no raphe (Sievers classification type 0)
  • Aortic valve is a congenital unicuspid or is non-calcified
  • Anomalous coronary artery that would interfere with proper placement of the valve

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the safety and effectiveness of the SAPIEN 3 (Edwards Lifesciences, Irvine, California) transcatheter heart valve implantation (TAVI) in Chinese patients with symptomatic severe calcific aortic stenosis who are considered at high risk for surgical valve replacement.

The group in the trial

  • Patients with SAPIEN 3 THVTreatment being tested

    Patients will be treated with Edwards SAPIEN 3 Transcatheter Heart Valve and Commander delivery system

    Treatment: SAPIEN 3 THV with the Commander delivery system

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 Transcatheter Heart Valve (THV) in the Chinese Population
Record updated
10 September 2025